Company Announcements

Additional Listing

Source: RNS
RNS Number : 7947G
Barclays PLC
19 March 2020
 

19 March 2020

 

Barclays PLC - Additional Listing

 

Barclays PLC (the "Company") confirms a listing application has been made for 26,491,561 ordinary shares of 25 pence each in the Company (the "Shares") to the Financial Conduct Authority for the Shares to be admitted to the Official List and to the London Stock Exchange for trading.  Dealings in the Shares are expected to commence on 3 April 2020.

 

The Shares will be issued to shareholders who are participants in the Company's Scrip Dividend Programme (the "Programme") in respect of the full year dividend for the year ended 31 December 2019, at a price of 144.92 pence per share. The Shares will rank equally with existing issued ordinary shares in the Company.

 

Copies of the following documents relating to the Programme are available on our website and in accordance with Listing Rule 9.6.1 have been submitted to the National Storage Mechanism, available for inspection at www.morningstar.co.uk/uk/NSM;

 

·   Scrip Dividend Programme Terms and Conditions 2018; and

·   Scrip Dividend Mandate Form.

 

 For further information, please contact:

 

Equiniti:

0371 384 2055* (in the UK)

+44 (0)121 415 7004 (from overseas)

 

*Lines are open 8.30am to 5.30pm (UK time), Monday to Friday, excluding public holidays in England and Wales

 

     Investor Relations                                                                                        Media Relations

     Chris Manners                                                                                              Tom Hoskin

     +44 (0)20 7773 2136                                                                                   +44 (0)20 7116 4755

 

   

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSJLMMTMTABBMM